This Week in General Medicine — Jun 9, 2026

Welcome to This Week in General Medicine. This week we're covering 7 notable papers spanning major advances in cardiovascular and renal care, new considerations for hospitalized older adults, a powerful new diabetes therapy, and a crucial intervention for physician wellbeing. Let's dive in.

We begin this week in cardiology and nephrology, with three major papers redefining preventative strategies. First, from The New England Journal of Medicine, the CHAMPION-AF trial challenges the standard of care for stroke prevention in atrial fibrillation [1]. In this large, randomized trial of nearly 3000 patients who were suitable candidates for anticoagulation, device-based left atrial appendage closure was compared directly to non-vitamin K antagonist oral anticoagulant, or NOAC, therapy. After 3 years of follow-up, the device was non-inferior to NOACs for the primary efficacy endpoint, a composite of cardiovascular death, stroke, or systemic embolism. The event rate was 5.7% in the device group versus 4.8% in the anticoagulation group, a difference that fell well within the pre-specified non-inferiority margin. More strikingly, the device was superior for the primary safety endpoint of non-procedure-related bleeding, which occurred in about 11% of the device group compared to 19% of the NOAC group. This translates to a hazard ratio of 0.55, meaning the device cut the risk of major bleeding by nearly half. These findings suggest that for patients with atrial fibrillation who are candidates for anticoagulation, left atrial appendage closure is a viable alternative, not just a last resort for those who cannot take blood thinners.

Continuing the theme of broad-spectrum organ protection, a large pooled analysis in The Lancet expands the role of the non-steroidal mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease [2]. This individual participant data meta-analysis, called INFINITY, combined three major randomized trials, including over 14,500 participants. The results show that finerenone reduced the risk of the composite kidney outcome — kidney failure or a sustained eGFR decline of 57% or more — by 24% compared to placebo. It also reduced the risk of kidney failure alone. The benefits extended to cardiovascular outcomes as well, with a 20% reduction in the composite of heart failure hospitalization or cardiovascular death, and an 18% reduction in cardiovascular death alone. Importantly, these protective effects were consistent across a wide range of patients, irrespective of their glycemic status, the underlying cause of their CKD, their baseline eGFR, or their level of albuminuria. While hyperkalemia was more frequent with finerenone, the absolute incidence of hyperkalemia leading to hospitalization was low. These robust findings support positioning finerenone as a foundational therapy for a broad population of patients with chronic kidney disease.

Rounding out our cardiovascular theme, a genetic substudy of the DECLARE-TIMI 58 trial, published in Nature Medicine, hints at a powerful role for SGLT2 inhibitors in primary prevention for a very high-risk group [3]. Investigators performed whole-exome sequencing on over 12,000 trial participants with type 2 diabetes to identify carriers of pathogenic or likely pathogenic variants in cardiomyopathy-associated genes. They found 121 such carriers. Over a median follow-up of 4.2 years, the SGLT2 inhibitor dapagliflozin lowered the risk of hospitalization for heart failure far more strongly in these genetic carriers than in non-carriers. The hazard ratio was a remarkable 0.18 in carriers versus 0.70 in non-carriers. This corresponded to an absolute risk reduction of 13% in carriers, compared to just 1% in non-carriers. The benefit was seen even in carriers with no prior heart failure diagnosis. While these results need confirmation in a dedicated prospective trial, they raise the possibility that SGLT2 inhibitors could be used early to prevent heart failure in individuals known to carry high-risk cardiomyopathy genes.

Next, we turn to two studies examining the downstream consequences of hospitalization in vulnerable older adults. First, a quasi-experimental study in the Annals of Internal Medicine questions the benefits of hospital admission for persons with dementia [4]. Using Medicare data from over 870,000 emergency department visits, researchers used an instrumental variable method to estimate the causal effect of admission. They found no evidence that hospital admission was associated with a change in 30-day mortality. The confidence interval was wide, compatible with anything from a 5.2 percentage point decrease to a 0.1 percentage point increase in mortality. However, hospital admission was clearly associated with higher downstream costs, adding an average of over $2,500 in healthcare spending in the 30 days following the visit. This study suggests that for patients with dementia, the decision to admit from the ED warrants careful consideration, as it may increase costs without providing a clear survival benefit.

In a related vein, a prospective cohort study in JAMA Internal Medicine investigated the link between postoperative delirium and long-term cognitive decline [5]. The prevailing hypothesis has been that this association is mediated by the overall illness and frailty that also leads to rehospitalizations. In a cohort of 560 older adults followed for 5 years after major elective surgery, delirium was indeed associated with a more marked rate of cognitive decline. Rehospitalizations were also linked to cognitive decline and were more common in patients who had experienced delirium. However, contrary to expectations, adjusting for rehospitalizations did not meaningfully change the strong association between delirium and cognitive decline. This finding suggests that delirium itself, rather than simply being a marker for frailty, may have a more direct or independent role in driving long-term cognitive injury.

In therapeutics, a phase 3 trial in The Lancet introduces a potent new combination therapy for type 2 diabetes [6]. The REIMAGINE 3 study evaluated CagriSema, a once-weekly injection combining the amylin analogue cagrilintide with the GLP-1 agonist semaglutide, as an add-on to basal insulin. In adults with a mean baseline HbA1c of 8.8%, the higher 2.4 mg dose of CagriSema produced a mean HbA1c reduction of 2.33 percentage points at 40 weeks, which was a 1.68 percentage point greater reduction than seen with placebo. This powerful glycemic control was accompanied by a robust bodyweight reduction of 10-12%. Adverse events were primarily mild-to-moderate gastrointestinal issues, and no severe hypoglycemia was reported. This combination appears to be a highly effective option for patients with type 2 diabetes who have inadequate control on basal insulin.

Finally, a pragmatic trial in JAMA addresses a critical issue for our profession: burnout among childbearing physicians in training [7]. This randomized trial across seven institutions in the northeastern United States provided a parental support package to 78 pregnant residents and fellows, comparing them to 78 peers receiving usual support. The package included a smart bassinet, a wearable breast pump, virtual perinatal support, and formal faculty mentorship. The primary outcome was the change in burnout from early pregnancy to 24 weeks postpartum. While burnout increased in both groups, the intervention group saw a significantly smaller increase. The difference was clinically meaningful, with a medium-to-large effect size, driven primarily by a reduction in interpersonal disengagement. This study provides strong evidence that tangible, institution-level support can meaningfully mitigate burnout during the vulnerable postpartum period for physician trainees.

If you only have time for one paper this week, make it the CHAMPION-AF trial in The New England Journal of Medicine [1]. It establishes left atrial appendage closure as non-inferior to NOACs for preventing major cardiovascular events and superior for preventing bleeding in patients who are eligible for anticoagulation, potentially shifting how we approach long-term stroke prevention in atrial fibrillation.

Here are the key takeaways from this week in General Medicine. First: For patients with atrial fibrillation who are candidates for anticoagulation, left atrial appendage closure is a reasonable alternative to NOACs, offering non-inferior protection against stroke and cardiovascular death with a significantly lower risk of non-procedural bleeding at 3 years [1]. Second: The non-steroidal MRA finerenone reduces the risk of both kidney disease progression and major cardiovascular events across a wide spectrum of patients with chronic kidney disease, supporting its use as a foundational therapy regardless of diabetes status, eGFR, or albuminuria level [2]. Third: In patients with type 2 diabetes on basal insulin, the combination of cagrilintide and semaglutide leads to substantial reductions in both HbA1c and body weight, offering a potent new therapeutic option [6]. Fourth: For older adults, be mindful that hospital admission for patients with dementia may not reduce short-term mortality but does increase costs [4], and that postoperative delirium's link to long-term cognitive decline appears to be independent of subsequent rehospitalizations, suggesting a more direct neurotoxic effect [5]. Finally: For our institutions, a pragmatic parental support package for childbearing trainees can significantly mitigate the rise in postpartum burnout, highlighting the importance of targeted, tangible support for physician well-being [7].

That's your roundup for This Week in General Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.